GSK3326595 (Pemrametostat, EPZ015938)

製品コードS8664 バッチS866401

化学情報

	Synonyms	EPZ015938	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₂₄H₃₂N₆O₃
	分子量	452.55	CAS No.	1616392-22-3
Solubility (25°C)*	体外	DMSO	90 mg/mL (198.87 mM)
		Ethanol	90 mg/mL (198.87 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Pemrametostat (GSK3326595, EPZ015938) は、経口活性のある強力かつ選択的なプロテインアルギニンメチルトランスフェラーゼ5 (PRMT5) 阻害剤であり、動物モデルにおいてin vitroおよびin vivoで腫瘍増殖を強力に阻害します。
in vitro	In SW480-ZEB2 cells, Pemrametostat (GSK3326595) and Santacruzamate A treatments both rescue the ZEB2-mediated E-cadherin promoter suppression, confirming that the ZEB2-mediated repression of E-cadherin in CRC cells is facilitated by PRMT5 and HDAC2.
in vivo	Pemrametostat (GSK3326595) reduces liver metastasis of CRC cells and completely inhibits the distant metastasis of SW620 cells in nude mice.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	SW480 cells
	濃度	100, 250, 500 nM
	反応時間	48 h
	実験の流れ	SW480+Vector and SW480+ZEB2 cells express plasmid pGL3-E-cadherin promoter-Luc. InPRMT5 (GSK3326595) and inHDAC2 (Santacruzamate A) were added to the cell medium, and luciferase activity was assayed, 48 h later, luciferase activity was assayed and normalized to Renilla. (E) SW620 cells express plasmid pGL3-E-cadherin promoter-Luc. This compound and inHDAC2 (Santacruzamate A) were added to the medium, and luciferase activity was assayed, 48 h later, luciferase activity was assayed and normalized to Renilla. (Data sourced from selleck products)
動物実験	動物モデル	Female BALB/c nude mice injected with SW620
	投薬量	100 mg/kg
	投与方法	i.v. (Data sourced from selleck products)

参考

https://pubmed.ncbi.nlm.nih.gov/28067760/
https://pubmed.ncbi.nlm.nih.gov/35884488/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C-Myc Feedback Loop [ MedComm (2020), 2025, 6(6):e70150]	PubMed: 40384988
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design [ J Med Chem, 2025, 68(4):4217-4236]	PubMed: 39919252
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion [ J Med Chem, 2025, 68(5):5097-5119]	PubMed: 40035511
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids [ NPJ Precis Oncol, 2024, 8(1):52]	PubMed: 38413740
Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition [ Elife, 2024, 12RP90683]	PubMed: 38682900
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers [ J Med Chem, 2024, 67(8):6064-6080.]	PubMed: 38595098
MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes With Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects [ Anticancer Res, 2024, 44(12):5231-5240]	PubMed: 39626906
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy [ Nat Metab, 2023, 10.1038/s42255-023-00861-4]	PubMed: 37563469
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy [ Nat Metab, 2023, 5(9):1544-1562]	PubMed: 37563469
MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression [ EMBO J, 2023, e114558.]	PubMed: 37905571

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。